{"classes":[{"categories":[{"measurements":[{"comment":"The median and upper limit of 95% confidence interval were not estimable due to very less number of participants with events.","groupId":"OG000","lowerLimit":"6.64","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"DoR calculated among responders from the date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease as defined in RECIST version 1.1 or death, whichever occurred first. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR is defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, in absence of new lesions or unequivocal progression of non-target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC) received apalutamide 240 milligrams (mg) (4\\*60 mg tablets) orally once daily with or without food in combination with stable regimen of goserelin 3.6 mg administered subcutaneously once per cycle (each cycle is of 28 days) as a gonadotropin-releasing hormone (GnRH) agonist, until disease progression, unacceptable toxicity, death, or end of the study.","id":"OG000","title":"Apalutamide + Goserelin"}],"paramType":"MEDIAN","populationDescription":"Population analyzed included response evaluable set amongst who were responders (CR or PR).","reportingStatus":"POSTED","timeFrame":"Up to 13 months","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"months"}